Product Program year 2019 Source: CMS Open Payments

Opsumit

Drug Cardiovascular Disorders

NDC 66215-501-30

Open in the dashboard

General payments

$619,797

1,177 payments

Research payments

$3,722,187

923 payments

Through program year 2019, $619,797 in general payments and $3,722,187 in research payments were reported against Opsumit (Cardiovascular Disorders).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2019 General $619,797 1,177
2019 Research $3,722,187 923

Breakdown

Who paid General payments · program year 2019
  1. Actelion Pharmaceuticals US, Inc. $402,757 1,130 payments
  2. Actelion Pharmaceuticals, Ltd $202,477 29 payments
  3. Janssen Research & Development, LLC $14,564 18 payments
Top recipients General payments · program year 2019
  1. Willis Maddrey Hepatology · Dallas, TX $99,906 16% · 14 payments
  2. James Freston Gastroenterology · Farmington, CT $61,271 10% · 9 payments
  3. Paul Watkins Gastroenterology · Chapel Hill, NC $30,125 5% · 3 payments
  4. Ashish Gupta Cardiovascular Disease · Phoenix, AZ $25,994 4% · 30 payments
  5. John McConnell Pulmonary Disease · Louisville, KY $23,500 4% · 21 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2019.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2019
  1. Pulmonary Disease Internal Medicine $148,453 25% · 279 practitioners
  2. Cardiovascular Disease Internal Medicine $104,485 17% · 188 practitioners
  3. Hepatology Internal Medicine $99,906 17% · 1 practitioner
  4. Gastroenterology Internal Medicine $91,396 15% · 2 practitioners
  5. Advanced Heart Failure and Transplant Cardiology Internal Medicine $84,188 14% · 29 practitioners

The top 5 of 34 specialties; each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2019
  1. Texas $119,234 19% · 58 recipients
  2. Connecticut $75,509 12% · 11 recipients
  3. North Carolina $57,659 9% · 26 recipients
  4. California $56,695 9% · 107 recipients
  5. Florida $41,782 7% · 78 recipients

The top 5 of 44 states; each share is of general payments naming this product in 2019 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

93,092

Prescriptions dispensed, refills included

Drug cost

$1,177,584,022

Paid at the pharmacy, in all

Prescribers

1,619

With 11 or more claims of it

Medicare Part D drugs matched to OPSUMIT, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Opsumit Macitentan Same name 1,619 93,092 $1,177,584,022

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Hunter Champion Cardiology GA 1,254 $15,855,959 $52,668
John McConnell Pulmonary Disease KY 946 $11,971,909 $36,511
Vallerie McLaughlin Cardiology MI 935 $11,815,162 $5,044
Murali Chakinala Pulmonary Disease MO 829 $10,519,049 $7,284
John Kingrey Pulmonary Disease OK 800 $9,973,163 $17,735

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
1,177 general · 923 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2019

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record